T32

Q3 Medicine Ejc Supplements Pub Date : 2015-11-01 DOI:10.1016/j.ejcsup.2015.08.037
T. Isayeva, M. Brandwein-Gensler
{"title":"T32","authors":"T. Isayeva,&nbsp;M. Brandwein-Gensler","doi":"10.1016/j.ejcsup.2015.08.037","DOIUrl":null,"url":null,"abstract":"<div><p>The most important development in head and neck oncology of the past decade is the demonstration that patients with human papillomavirus (HPV)-mediated oropharyngeal cancers have significantly improved outcomes, compared to HPV-negative counterpart patients.</p><p>We examined racial disparities among 102 oropharyngeal carcinoma (OPC) patients (30 African Americans, 72 Whites) comparing the present of HPV16/18 E6 and E7 oncoproteins, and p16Ink4A overexpression, with times to disease progression (DP) and disease specific survival (DSS). Expression of HPV16/18 transcripts was assessed by reverse transcription and polymerase chain reaction using type-specific E6/E7 primers; p16Ink4A was evaluated by immunohistochemistry. African Americans were significantly more likely to present with high T stage disease and receive nonsurgical treatment. HPV16/18 was present in 63% of patients; no racial differences were observed. Silenced p16Ink4A in OPC was significantly more common in African Americans (15/24) than Whites (20/69) (<em>p</em> <!-->=<!--> <!-->0.004), and HPV16<!--> <!-->+<!--> <!-->African Americans (6/24) than HPV<!--> <!-->+<!--> <!-->Whites (2/42) (<em>p</em> <!-->=<!--> <!-->0.023). Kaplan Meier analysis for DSS revealed a protective effect for p16Ink4A overexpression (<em>p</em> <!-->=<!--> <!-->0.0028), HPV16+ (<em>p</em> <!-->=<!--> <!-->0.036), and Whites (<em>p</em> <!-->=<!--> <!-->0.0039). Shorter DSS was associated with primary definitive chemoradiation (<em>p</em> <!-->=<!--> <!-->0.019) and T3/T4 disease (<em>p</em> <!-->=<!--> <!-->0.0001). A protective effect with respect to disease progression was observed for HPV16+ (<em>p</em> <!-->=<!--> <!-->0.007), Whites (<em>p</em> <!-->=<!--> <!-->0.0006) and p16Ink4A overexpression (<em>p</em> <!-->=<!--> <!-->0.0001). African Americans with OPC experience poorer outcomes likely due to p16Ink4A silencing, higher T stage, and nonsurgical treatment, but not lower rates of transcriptionally active HPV16/18.</p><p>We studied patients with oral cavity squamous cell carcinoma for HPV16 and HPV18, local immune response, p16 expression and outcome.</p><p>Overexpression of p16INK4a was uncommon in oral cavity squamous cell carcinoma (17/112 or 15.2%). HPV16 and HPV18 were detected in 22.6% and 11% patients respectively. We demonstrated that the presence of transcriptionally active HPV16 in oral cavity squamous cell carcinomas does not correlate with p16INK4a overexpression, enhanced local tumor immunity, or improved outcome. To investigate the possible mechanism of protective effect of HPV and p16INK4a, we have developed primary cancer cell lines from resections with known patterns of invasion. Given that cell lines derived from HPV-mediated oropharyngeal squamous cell carcinomas are less invasive than their HPV-negative counterparts, we tested the hypothesis that viral oncoproteins E6, E7, and p16INK4a can affect tumor invasion. We demonstrated that p16INK4a overexpression in two cancer cell lines (UAB-3 and UAB-4), derived from oral cavity squamous cell carcinomas with the most aggressive invasive phenotype, dramatically decrease tumor invasiveness by altering expression of extracellular matrix remodeling genes. Pathway analysis integrating changes in RNA expression and kinase activities reveals different potential p16INK4a-sensitive pathways. In summary, we presented clinical data from a large cohort of head and neck squamous cell carcinoma patients with respect to transcriptionally active HPV16, p16INK4a overexpression, local adaptive tumor immunity, and outcome. Observed differences in clinical outcomes could be perhaps due to differential immune responses and gene activation profile. The detection of a HPV-positivity in HNSCC has important clinical implications as independent prognostic factor for treatment deintensification and improved survival of HPV-mediated oropharyngeal cancers. In our knowledge the further studies are needed to dissect the HPV-positive HNSCC in more detail to find the effective prognostic markers as well as molecular targets to affect tumor behavior.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"13 1","pages":"Page 21"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.037","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634915000385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The most important development in head and neck oncology of the past decade is the demonstration that patients with human papillomavirus (HPV)-mediated oropharyngeal cancers have significantly improved outcomes, compared to HPV-negative counterpart patients.

We examined racial disparities among 102 oropharyngeal carcinoma (OPC) patients (30 African Americans, 72 Whites) comparing the present of HPV16/18 E6 and E7 oncoproteins, and p16Ink4A overexpression, with times to disease progression (DP) and disease specific survival (DSS). Expression of HPV16/18 transcripts was assessed by reverse transcription and polymerase chain reaction using type-specific E6/E7 primers; p16Ink4A was evaluated by immunohistochemistry. African Americans were significantly more likely to present with high T stage disease and receive nonsurgical treatment. HPV16/18 was present in 63% of patients; no racial differences were observed. Silenced p16Ink4A in OPC was significantly more common in African Americans (15/24) than Whites (20/69) (p = 0.004), and HPV16 + African Americans (6/24) than HPV + Whites (2/42) (p = 0.023). Kaplan Meier analysis for DSS revealed a protective effect for p16Ink4A overexpression (p = 0.0028), HPV16+ (p = 0.036), and Whites (p = 0.0039). Shorter DSS was associated with primary definitive chemoradiation (p = 0.019) and T3/T4 disease (p = 0.0001). A protective effect with respect to disease progression was observed for HPV16+ (p = 0.007), Whites (p = 0.0006) and p16Ink4A overexpression (p = 0.0001). African Americans with OPC experience poorer outcomes likely due to p16Ink4A silencing, higher T stage, and nonsurgical treatment, but not lower rates of transcriptionally active HPV16/18.

We studied patients with oral cavity squamous cell carcinoma for HPV16 and HPV18, local immune response, p16 expression and outcome.

Overexpression of p16INK4a was uncommon in oral cavity squamous cell carcinoma (17/112 or 15.2%). HPV16 and HPV18 were detected in 22.6% and 11% patients respectively. We demonstrated that the presence of transcriptionally active HPV16 in oral cavity squamous cell carcinomas does not correlate with p16INK4a overexpression, enhanced local tumor immunity, or improved outcome. To investigate the possible mechanism of protective effect of HPV and p16INK4a, we have developed primary cancer cell lines from resections with known patterns of invasion. Given that cell lines derived from HPV-mediated oropharyngeal squamous cell carcinomas are less invasive than their HPV-negative counterparts, we tested the hypothesis that viral oncoproteins E6, E7, and p16INK4a can affect tumor invasion. We demonstrated that p16INK4a overexpression in two cancer cell lines (UAB-3 and UAB-4), derived from oral cavity squamous cell carcinomas with the most aggressive invasive phenotype, dramatically decrease tumor invasiveness by altering expression of extracellular matrix remodeling genes. Pathway analysis integrating changes in RNA expression and kinase activities reveals different potential p16INK4a-sensitive pathways. In summary, we presented clinical data from a large cohort of head and neck squamous cell carcinoma patients with respect to transcriptionally active HPV16, p16INK4a overexpression, local adaptive tumor immunity, and outcome. Observed differences in clinical outcomes could be perhaps due to differential immune responses and gene activation profile. The detection of a HPV-positivity in HNSCC has important clinical implications as independent prognostic factor for treatment deintensification and improved survival of HPV-mediated oropharyngeal cancers. In our knowledge the further studies are needed to dissect the HPV-positive HNSCC in more detail to find the effective prognostic markers as well as molecular targets to affect tumor behavior.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
T32
过去十年头颈部肿瘤学最重要的发展是,与HPV阴性患者相比,人乳头瘤病毒(HPV)介导的口咽癌患者的预后显著改善。我们研究了102名口咽癌(OPC)患者(30名非洲裔美国人,72名白人)的种族差异,比较了HPV16/18 E6和E7癌蛋白的存在,以及p16Ink4A的过表达,与疾病进展(DP)和疾病特异性生存(DSS)的时间。采用E6/E7型特异性引物,通过逆转录和聚合酶链反应检测HPV16/18转录本的表达;免疫组织化学检测p16Ink4A。非裔美国人更有可能出现高T期疾病并接受非手术治疗。63%的患者存在HPV16/18;没有观察到种族差异。沉默的p16Ink4A在OPC中非洲裔美国人(15/24)比白人(20/69)更常见(p = 0.004), HPV16 +非洲裔美国人(6/24)比HPV +白人(2/42)更常见(p = 0.023)。Kaplan Meier分析显示,DSS对p16Ink4A过表达(p = 0.0028)、HPV16+ (p = 0.036)和Whites (p = 0.0039)具有保护作用。较短的DSS与原发性明确放化疗(p = 0.019)和T3/T4疾病(p = 0.0001)相关。HPV16+ (p = 0.007)、Whites (p = 0.0006)和p16Ink4A过表达(p = 0.0001)对疾病进展有保护作用。非裔美国人OPC的预后较差,可能是由于p16Ink4A沉默,更高的T期和非手术治疗,但转录活性HPV16/18的发生率较低。我们研究了口腔鳞状细胞癌患者的HPV16和HPV18,局部免疫反应,p16表达和预后。p16INK4a过表达在口腔鳞状细胞癌中并不常见(17/112或15.2%)。HPV16和HPV18的检出率分别为22.6%和11%。我们证明,在口腔鳞状细胞癌中,转录活性HPV16的存在与p16INK4a过表达、局部肿瘤免疫增强或预后改善无关。为了研究HPV和p16INK4a保护作用的可能机制,我们从已知侵袭模式的切除中培养了原发癌细胞系。鉴于hpv介导的口咽鳞状细胞癌细胞系的侵袭性低于hpv阴性细胞系,我们验证了病毒癌蛋白E6、E7和p16INK4a可以影响肿瘤侵袭的假设。我们证明p16INK4a在两种来自口腔鳞状细胞癌的细胞系(UAB-3和UAB-4)中过表达,通过改变细胞外基质重塑基因的表达显著降低肿瘤的侵袭性。整合RNA表达和激酶活性变化的通路分析揭示了不同的潜在p16ink4a敏感通路。总之,我们提供了来自大量头颈部鳞状细胞癌患者的临床数据,涉及转录活性HPV16、p16INK4a过表达、局部适应性肿瘤免疫和结局。观察到的临床结果的差异可能是由于不同的免疫反应和基因激活谱。在HNSCC中检测hpv阳性具有重要的临床意义,作为hpv介导的口咽癌治疗去强化和改善生存的独立预后因素。据我们所知,需要进一步的研究来更详细地解剖hpv阳性的HNSCC,以找到有效的预后标志物以及影响肿瘤行为的分子靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ejc Supplements
Ejc Supplements 医学-肿瘤学
自引率
0.00%
发文量
0
审稿时长
3.7 months
期刊介绍: EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites. EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention. Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief. EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).
期刊最新文献
99mTc/123I Dual-Radionuclide Correction for Self-Scatter, Down-Scatter, and Tailing Effect for a CZT SPECT with Varying Tracer Distributions. Pre-COVID-19 Disparities in Telemedicine Use Among Louisiana Medicaid Beneficiaries. The importance of basal-temporal white matter to pre- and post-surgical naming ability in temporal lobe epilepsy. Editorial board Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1